Recent Finacing
Recent Raise
NeuroVia develops NV1205, a small-molecule disease-modifying therapy for X‑ALD, advancing toward clinical proof-of-concept after preclinical reduction of VLCFAs in ABCD1-deficient mouse brain, adrenal, and blood.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors